FTM
BECOME A MEMBER
() () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () ()

Tag Archives: 31R

  • Home
  •  | 
  • Tag Archives: "31R"

Revive Therapeutics Provides Corporate Update

Revive Therapeutics Provides Corporate Update
Revive is focused on commercializing differentiated cannabis-based products that have patent protection and best-in-class with first mover advantage offering a better alternative over conventional cannabis-based products in the market.  The Company’s patent portfolio includes exclusive rights to five issued U.S. patents, one issued Canadian patent and two patent applications filed in the U.S., based on cannabinoid delivery systems and uses for specific diseases.  The Company’s first product to be launched in Canada is a proprietary, unique hemp-based cannabidiol (“CBD”) chewing gum, which Revive signed an exclusive distribution and license agreement with AXIM® Biotechnologies, Inc. to market the product throughout Canada.  The Company anticipates launching its hemp-based CBD chewing gum product under Revive’s brand in the fourth quarter of this year.
Read more

Revive Therapeutics Applies To FDA For Orphan Drug Designation of Cannabidiol For Treatment Of Liver Transplantation

Liver ischemia-reperfusion injury is a major complication of liver transplantation and is one of the leading causes for post-surgery hepatic dysfunction leading to an increased risk of postoperative morbidity and mortality.  According to the United Network for Organ Sharing (“UNOS”) there have been 160,722 liver transplants performed between January 1, 1988 and July 30, 2018.  Currently there are 13,773 individuals on the waiting list for a liver transplant.  Quickly restoring blood supply of ischemic liver as soon as possible is crucial for avoiding or reducing injury from ischemia, whereas strategies used to attenuate the damage induced by reperfusion, including ischemic preconditioning, ischemic postconditioning, and machine perfusion.  These strategies are expensive, sometimes hard to perform in clinical surgeries, and difficult in maintaining liver functions in the case of acute injuries.  Revive believes that the immunosuppressant and anti-inflammatory protective effects of CBD  may provide a novel, more beneficial strategy to attenuate the damage induced by ischemia and reperfusion during liver transplantation.
Read more